{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:18:08Z","timestamp":1778818688907,"version":"3.51.4"},"reference-count":31,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/17512433.2021.1901579","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T09:15:46Z","timestamp":1615454146000},"page":"545-551","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action"],"prefix":"10.1080","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-6541","authenticated-orcid":false,"given":"Huyen","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, The Ben and Maytee Fisch College of Pharmacy, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikenna","family":"Akamnonu","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, The Ben and Maytee Fisch College of Pharmacy, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianrui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, The Ben and Maytee Fisch College of Pharmacy, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"cit0001","volume-title":"Centers for disease control and prevention)","author":"High Cholesterol Facts"},{"key":"cit0002","first-page":"2019","volume":"139","author":"Grundy SM","year":"2018","journal-title":"Circulation"},{"key":"cit0003","author":"Omudhome Ogbru PD.","journal-title":"MedicineNet"},{"key":"cit0004","volume-title":"PCSK9 Inhibitors: a technology worth paying for? Switzerland: PharmacoEconomics","author":"Weintraub WS"},{"key":"cit0005","unstructured":"PCSK9 inhibitors: pharmacology, adverse effects, and use. UpToDate. https:\/\/www.uptodate.com\/contents\/pcsk9-inhibitors-pharmacology-adverse-effects-and-use Accessed 2020 Nov 1."},{"key":"cit0006","unstructured":"Danaf JA, Martin SS, Blumenthal RS. Ezetimibe: the Lower the LDL-C, the Better (Even for Total Cardiovascular Events). Am Coll Cardiol. [2020 Nov 30]. Accessed: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2016\/03\/09\/06\/50\/ezetimibe-the-lower-the-ldlc-the-better"},{"key":"cit0007","unstructured":"Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process Accessed 2020 Nov 1."},{"key":"cit0008","unstructured":"NEXLETOL (bempedoic acid) tablets, for oral use. Initial U.S. Approval: 2020 . https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211616s000lbl.pdf Accessed 2020 Nov 1."},{"key":"cit0009","unstructured":"NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe): Mechanism of Action. NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) | mechanism of Action. https:\/\/www.nexletolhcp.com\/mechanism-of-action?gclid=Cj0KCQjwwuD7BRDBARIsAK_5YhXrMgm3Ht-rEd_LZQiXQPStZtn5l8Bw7rdMnkwWwZQehdiHz4hJXZUaApZtEALw_wcB Accessed 2020 Nov 1."},{"key":"cit0010","volume-title":"Center for drug evaluation and research - application number: 211616Orig1s000"},{"issue":"380","key":"cit0011","volume":"380","author":"Ray KK","year":"2019","journal-title":"N Engl J Med"},{"key":"cit0012","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the clear wisdom randomized clinical trial [published correction appears in the Journal of the American Medical Association (JAMA). 2020;323(11):1095\u20131096."},{"issue":"277","key":"cit0013","volume":"277","author":"Ballantyne CM","year":"2018","journal-title":"Atherosclerosis"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662"},{"key":"cit0015","unstructured":"Assessment of the long-term safety and efficacy of bempedoic acid (CLEAR Harmony OLE) - full text view. Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03067441. Accessed 2020 Dec 1."},{"key":"cit0016","unstructured":"Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo - Full Text View. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo - full text view - clinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406 Accessed 2020 Dec 1."},{"issue":"2","key":"cit0017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5603\/KP.a2019.0013","volume":"77","author":"Wang X","year":"2019","journal-title":"Kardiol Pol"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.06.028"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003121"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00989-1"},{"key":"cit0021","unstructured":"Minno AD, Lupoli R, Calcaterra I, et al. J Am Heart Assoc. 2020 efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta\u2010analysis of randomized controlled trials. [online] Available at: https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.119.016262 [Accessed 2020 Sept 4"},{"key":"cit0022","author":"Weber C","journal-title":"Circ Res"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011581"},{"key":"cit0024","unstructured":"www.heart.org. 2020. Cholesterol Medications. [online] Available at: https:\/\/www.heart.org\/en\/health-topics\/cholesterol\/prevention-and-treatment-of-high-cholesterol-hyperlipidemia\/cholesterol-medications [Accessed 2020 Nov 25]."},{"key":"cit0025","unstructured":"Rees V. EC approves Nilemdo\u2122 (bempedoic acid) for lowering cholesterol. European Pharmaceutical Review. https:\/\/www.europeanpharmaceuticalreview.com\/news\/116601\/ec-approves-nilemdo-bempedoic-acid-for-lowering-cholesterol\/#:~:text=The%20European%20Commission%20(EC)%20has,LDL%2DC)%20lowering%20medicine Published April 9, 2020; Accessed 2021 Jan 26"},{"key":"cit0026","volume-title":"Esperion announces agreement with otsuka pharmaceutical co., ltd. for development and commercialization of NEXLETOL\u2122 (bempedoic acid) and NEXLIZET\u2122 (bempedoic acid and ezetimibe) tablets in japan"},{"key":"cit0027","author":"Karatasakis A","journal-title":"J Am Heart Assoc"},{"key":"cit0028","doi-asserted-by":"crossref","unstructured":"Doshi JA, Jalpa A, Puckett JT, et al. \u201cPrior authorization requirements for proprotein convertase subtilisin\/kexin type 9 inhibitors across us private and public payers.\u201d Circulation: Cardiovascular Quality and Outcomes. https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/circoutcomes.117.003939 Published January 11, 2018. Accessed 2020 Dec 26.","DOI":"10.1161\/CIRCOUTCOMES.117.003939"},{"key":"cit0029","volume-title":"Lexi-Drugs"},{"key":"cit0030","unstructured":"www.heart.org. 2020. Cholesterol medications. [online] Available at: https:\/\/www.heart.org\/en\/health-topics\/cholesterol\/prevention-and-treatment-of-high-cholesterol-hyperlipidemia\/cholesterol-medications [Accessed 2020 Aug 25] ."},{"key":"cit0031","unstructured":"Understanding your cholesterol report. [online] WebMD. Available at: https:\/\/www.webmd.com\/cholesterol-management\/understanding-your-cholesterol-report [Accessed 2020 Aug 25]"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2021.1901579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T17:56:56Z","timestamp":1622829416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2021.1901579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/17512433.2021.1901579"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2021.1901579","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}